ArticleClinical oral investigations2026
Characterization of oral microbiome in atopic dermatitis patients treated with dupilumab or upadacitinib.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDysbiosis, an imbalanced state of microbial communities in the human body, may contribute to autoimmune diseases such as atopic dermatitis (AD). While the role of affected skin-gut microbiome axis in AD is well established, still little is known about the relationship between oral microflora-based dysbiosis and AD progression and treatment. MATERIALS AND
methods16S rRNA gene amplicon sequencing of the V3-V4 hypervariable region was used to characterize the bacterial profiles of saliva samples from fifteen AD patients treated with dupilumab, an antibody against interleukin-4 receptor, or upadacitinib, an inhibitor of JAK1 kinase, for sixteen weeks. Oral microbiome data were compared with the Eczema Area and Severity Index (EASI).
resultsAnalysis revealed that at phylum level, Actinomycetota decreased significantly upon treatment (from a median of 11.87% to 6.15%; q = 0.0094), with a reciprocal increase in Bacteroidota (from 19.78% to 28.39%; q = 0.0185).
conclusionsAlthough all patients showed clinical improvement, the cohort did not permit assessment of a dose-response relationship between EASI score and Actinomycetota abundance. Thus, larger, more heterogeneous cohorts and mechanistic data (e.g., metabolomics-based identification of microbiome-derived metabolites) are needed to validate these findings and clarify their relevance as a potential therapeutic marker in AD. CLINICAL RELEVANCE: The parallel decline in oral Actinomycetota abundance and EASI score highlights a potential link between the oral microbiome and treatment response in AD, warranting further investigation. In the absence of non-responders, this association does not yet support Actinomycetota as a potential biomarker of treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.